In recent years, several marine heterotrophic nanoflagellates have been reported to feed on diatoms much larger than themselves. However, very little is known about the grazer-prey relationships between heterotrophic ...In recent years, several marine heterotrophic nanoflagellates have been reported to feed on diatoms much larger than themselves. However, very little is known about the grazer-prey relationships between heterotrophic nanoflagellates and diatoms in aquatic ecosystems. A diatom-feeding flagellate was discovered in the bottom sediment of OnagawaBay. It fed and proliferated on diatoms, especially Skeletonema costatum sensu lato. This study determined growth and ingestion rates of the flagellate on Skeletonema costatum s.l. under laboratory conditons. Its grazing pressure on the sinking flux of S. costatum s.l. was calculated by combining field data. Specific growth rate of the flagellate increased with increasing prey concentration. The maximum specific growth rate was 0.79 d–1 and maximum ingestion rate of the flagellate was 0.66 ng·C·grazer–1·d–1. Calculated grazing pressure of the flagellate on S. costatum s.l. flux was up to 25.6%. The results imply that the flagellate has a considerable grazing impact on S. costatum s.l. flux at least in a restricted season of the year. Therefore, the present study suggests that this benthic flagellate plays an important role in pelagic-benthic coupling inOnagawaBay.展开更多
Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled...Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and 17 patients completed the study (mean age: 73 years and GOLD I/II/III/IV, 5/10/1/1). The mean CAT scores significantly improved (9.2 to 5.4, p = 0.015) and 10 patients (58.8%) showed ≥2 points improvement, a minimal clinically important difference. The mean FeNO levels significantly decreased from 63.0 to 34.3 ppb (p Conclusions: FeNO-guided treatment with BUD/FM improves symptoms in patients with ACO.展开更多
文摘In recent years, several marine heterotrophic nanoflagellates have been reported to feed on diatoms much larger than themselves. However, very little is known about the grazer-prey relationships between heterotrophic nanoflagellates and diatoms in aquatic ecosystems. A diatom-feeding flagellate was discovered in the bottom sediment of OnagawaBay. It fed and proliferated on diatoms, especially Skeletonema costatum sensu lato. This study determined growth and ingestion rates of the flagellate on Skeletonema costatum s.l. under laboratory conditons. Its grazing pressure on the sinking flux of S. costatum s.l. was calculated by combining field data. Specific growth rate of the flagellate increased with increasing prey concentration. The maximum specific growth rate was 0.79 d–1 and maximum ingestion rate of the flagellate was 0.66 ng·C·grazer–1·d–1. Calculated grazing pressure of the flagellate on S. costatum s.l. flux was up to 25.6%. The results imply that the flagellate has a considerable grazing impact on S. costatum s.l. flux at least in a restricted season of the year. Therefore, the present study suggests that this benthic flagellate plays an important role in pelagic-benthic coupling inOnagawaBay.
文摘Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and 17 patients completed the study (mean age: 73 years and GOLD I/II/III/IV, 5/10/1/1). The mean CAT scores significantly improved (9.2 to 5.4, p = 0.015) and 10 patients (58.8%) showed ≥2 points improvement, a minimal clinically important difference. The mean FeNO levels significantly decreased from 63.0 to 34.3 ppb (p Conclusions: FeNO-guided treatment with BUD/FM improves symptoms in patients with ACO.
